---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030972"
form_type: "8-K"
ticker: "NXGL"
cik: "0001468929"
company_name: "NEXGEL, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:21:27.373360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NEXGEL Q3 revenue up 69.6% to $568k; gross margin improves to 26%

## Summary
- Revenue $568k, +69.6% YoY; growth driven by branded consumer products.
- Gross profit margin 26%, improved from negative margin in prior year; anticipates continued expansion.
- Operating expenses $1.2M include $220k one-time franchise tax; R&D spending increased to $193k from $0.
- Cash and marketable securities $7.4M; expects runway through 2024 to support R&D growth.
- Positive results from proof-of-concept study for diclofenac hydrogel pain patches; new proprietary amblyopia eye patch developed.

## SEC filing metadata
- accession: 0001493152-22-030972
- form_type: 8-K
- ticker: NXGL
- cik: 0001468929
- company_name: NEXGEL, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/0001493152-22-030972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030972
- JSON: https://secwatch.observer/filing/0001493152-22-030972.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030972.txt

## Key facts
- Earnings Releases
  NEXGEL, INC. reported third quarter ended September 30, 2022 results: revenue $568 thousand.
  - Period: third quarter ended September 30, 2022
  - Revenue: $568 thousand
  - Result: reported results
  source text: demonstrated significant scar improvement in patients treated with SilverSeal. Third Quarter 2022 Financial Highlights Revenue for the three months ended September 30, 2022 was $568 thousand, an increase of 69.6%, when compared to $233 thousand for the three months ended September 30, 2021. The increase in overall revenue was due to sales growth in branded consumer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/0001493152-22-030972-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.